Restoring Facial Volume After GLP-1 Weight Loss With Radiesse

Recruiting now · Phase 4

Conditions studied: Volume Loss (Soft Tissue Ptosis or Atrophy )

In brief

The goal of this clinical trial is to evaluate the potential of Calcium Hydroxylapatite (CaHA) to restore facial volume and improve skin quality in patients with GLP-1 receptor agonist-associated facial volume loss. Participants will: * Schedule first dose of a prescribed GLP-1 receptor agonist drug to coincide with the baseline visit of this study * Be randomly assigned to one of two groups (Group A will receive off-label injections of hyperdiluted CaHA at Month 0. Group B will receive on-label injections of CaHA after serving as a control group through Month 6) * Have clinical photos taken at each office visit to track progress

Key facts

Study ID: NCT07419854
Run by: Kalpna Kay Durairaj, MD, FACS
People needed: 48
Starts: 2026-02-01
Expected to finish: 2027-09-01
Last updated by the study team: 2026-02-19

Who can join

Age: 21 and older, up to 65. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

Adults aged 21-65 who are initiating GLP-1 therapy (semaglutide, tirzepatide, or similar) for weight loss or diabetes-related weight management with targeted weight loss of 20 pounds or more
Participants must have a body mass index (BMI) meeting indications for GLP-1 therapy and within the range of 24-32
Participants should be at the start of GLP-1 therapy (baseline visit scheduled at or within 1-2 weeks of first GLP-1 injection) so that baseline facial measurements represent their pre-weight-loss state
Participants must have noticeable facial subcutaneous fat (no pre-existing extreme lipoatrophy) and be willing to receive facial filler injections
Participants should be able to comply with all study visits and procedures up to 12 months
Participants must provide written informed consent, including consent for facial imaging

You may not qualify if…

Participants with any prior facial cosmetic procedures that could confound results e.g. facial filler or fat transfer in the past 2 years; thread lifts or energy based device facial treatments in the last 1 year; microneedling, botulinum toxin treatment in the depressor anguli oris (DAO), or chemical peels in the last 4 months; or a history of surgical lifts and/or liposuction
Participants currently using a retinoid
Participants with active dermatologic conditions affecting the face (e.g. severe acne, psoriasis on face) or scars that would interfere with volume assessment
Participants with known allergies or hypersensitivity to CaHA or lidocaine (lidocaine allergy)
Those with a history of severe anaphylactic reactions requiring epinephrine (due to risk with injectables)
Those with uncontrolled diabetes or major comorbid conditions that would make participation unsafe (e.g. bleeding disorders that contraindicate injections, immunosuppression that raises infection risk, uncontrolled psychiatric illness such as body dysmorphic disorder)
Pregnant or breastfeeding women are excluded (GLP-1 therapies are contraindicated in pregnancy, and elective filler is avoided in pregnancy)
Women of childbearing potential must agree to use an effective contraceptive method during the study (though pregnancy during the short study window is unlikely, this is a precaution)
If a Participant becomes pregnant or initiates any new facial cosmetic treatment during the Study, they will be withdrawn
Participants planning bariatric surgery or other significant weight loss interventions (besides the GLP-1 medication) in the study period

Where it is running

K. Kay Durairaj, MD, A Medical Corp. — Pasadena, California, United States (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.